Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blues TEC Assessment Endorses CRT For Mild Heart Failure

This article was originally published in The Gray Sheet

Executive Summary

Using cardiac resynchronization therapy to treat patients suffering from mild heart failure is supported by existing clinical evidence. That is not the case, however, for asymptomatic patients, according to a new assessment issued by Blue Cross Blue Shield’s Technology Evaluation Center.
Advertisement

Related Content

More Patients Should Receive Cardiac Resynchronization Therapy, Heart Groups Say
News In Brief
News In Brief
Medtronic’s RAFT Keeps Hopes Afloat For Shift To CRT In Milder Heart Failure
Boston Scientific Gains Expanded Indication For CRT-D Devices
Boston Scientific Gains Expanded Indication For CRT-D Devices
ESC Guidelines: CRT Gets Nod For Mild Symptoms, But Not Asymptomatic HF
FDA Panel Endorses Expanded Approval For Boston Scientific CRT-Ds

Topics

Advertisement
UsernamePublicRestriction

Register

MT030450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel